Eli Lilly is making a $6.3 billion play for Centessa Pharmaceuticals, acquiring the UK-based biotech and its late-stage narcolepsy candidate in a deal announced March 31.

The all-cash acquisition gives Lilly a direct shot at the lucrative—and underserved—market for sleep disorder treatments. Centessa’s lead asset, a Phase 3 narcolepsy therapy, is the centerpiece of the deal and positions Lilly to compete head-to-head with established sleep disorder brands.

Why It Matters: Pipeline Power, Premium Price

The $6.3 billion price tag represents a significant premium over Centessa’s recent market valuation, underscoring big pharma’s hunger for late-stage neuroscience assets. Lilly’s move is the latest in a string of high-stakes bets by major drugmakers on rare disease and CNS portfolios, as the industry pivots from primary care blockbusters to high-value specialty drugs.

Centessa shareholders will receive the full $6.3 billion in cash when the deal closes, expected in the second half of 2026, pending regulatory and shareholder approvals. The acquisition is set to further consolidate Lilly’s position in the competitive market for innovative neurological therapies, a sector with both high unmet need and commercial upside.

Centessa’s Narcolepsy Candidate: The Real Prize

Centessa’s lead narcolepsy drug is currently in Phase 3 trials, targeting a condition that affects an estimated 3 million people globally. Existing treatments are limited and often come with safety or efficacy trade-offs, creating an opening for new entrants with differentiated mechanisms or better tolerability.

For Lilly, which has been aggressively expanding its neuroscience and rare disease portfolio, Centessa’s late-stage asset offers a fast track to market leadership in sleep medicine. The company is betting that Centessa’s candidate can deliver both clinical impact and commercial returns, especially as payers and providers seek alternatives to aging therapies.

Big Pharma’s New M&A Playbook

This deal is emblematic of the broader M&A wave sweeping the pharmaceutical sector. As R&D costs climb and blockbuster patents expire, major players are turning to bolt-on acquisitions to fill pipeline gaps—especially in areas like neurology, where patient need is high and regulatory pathways are increasingly well-defined.

• Deal value: $6.3 billion in cash
• Target: Centessa Pharmaceuticals (UK-based biotech)
• Lead asset: Narcolepsy drug in Phase 3 clinical trials
• Expected close: H2 2026, pending approvals

Lilly’s move follows recent high-profile neuroscience deals by peers, including Biogen’s $7.3 billion Reata buyout and Pfizer’s $5.4 billion Global Blood Therapeutics acquisition. The message: if you want to win in rare disease and CNS, you buy late-stage assets, and you pay up.

Market Context: Sleep Disorders in the Spotlight

The sleep disorder market is drawing fresh attention as diagnosis rates climb and new mechanisms are validated in late-stage trials. Analysts estimate the global narcolepsy drug market could surpass $3 billion annually by 2030, with double-digit growth driven by new therapies and expanded indications.

For Lilly, the Centessa deal is more than a pipeline patch. It’s a signal that the company sees neuroscience—and sleep disorders in particular—as a core growth driver for the next decade.

What to Watch Next

The Centessa acquisition is slated to close in the back half of 2026, assuming regulators and shareholders sign off. The real test will be whether Centessa’s narcolepsy candidate can clear Phase 3 and deliver on its commercial promise. If so, Lilly could emerge as a dominant force in the sleep medicine market—setting the pace for further consolidation and innovation in neuroscience.

Bottom line: Lilly is betting big that late-stage neuroscience assets are worth the premium. If this gamble pays off, expect more M&A—and more competition—in the race to treat rare and neglected brain disorders.